Global Varicella Attenuated Live Vaccine Market to Grow at 4.7% CAGR According to a newly published market research report by 24LifeSciences, global varicella attenuated live vaccine market was valued at USD 2.44 billion in 2024 and is projected to reach USD 3.33 billion by 2032, growing at a compound annual growth rate (CAGR) of 4.7% during the forecast period 2025-2032. Varicella attenuated live vaccines are biological preparations derived from the Oka strain of varicella-zoster virus (VZV), specifically engineered to provide immunity against chickenpox. These vaccines contain weakened live viruses that stimulate an immune response without causing the disease, offering long-term protection against this highly contagious illness. The vaccine is available in both monovalent formulations (targeting only varicella) and combination vaccines (such as MMRV, which protects against measles, mumps, rubella, and varicella simultaneously). Download a Free Sample Report (PDF): https://www.24lifesciences.com/download-sample/1170/varicella-attenuated-live-vine-market